A group of cardiologists is scheduled to meet Thursday to discuss whether to recommend FDA approval for the expanded use of Johnson & Johnson's Thermocool line of catheters in treating atrial fibrillation. The agency is expected to ask the experts to comment on discrepancies between the results of studies conducted within and outside the U.S.

Full Story:

Related Summaries